## Laura Cosmai

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6928819/publications.pdf

Version: 2024-02-01

|                | 430874       | 454955                            |
|----------------|--------------|-----------------------------------|
| 1,024          | 18           | 30                                |
| citations      | h-index      | g-index                           |
|                |              |                                   |
|                |              |                                   |
|                |              |                                   |
| 57             | 57           | 1449                              |
| docs citations | times ranked | citing authors                    |
|                |              |                                   |
|                | citations 57 | 1,024 18 citations h-index  57 57 |

| #  | Article   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | Treatment of acute kidney injury in cancer patients. CKJ: Clinical Kidney Journal, 2022, 15, 873-884.   | 2.9 | 6         |
| 2  | Preventive strategies for acute kidney injury in cancer patients. CKJ: Clinical Kidney Journal, 2021, 14, 70-83.  | 2.9 | 28        |
| 3  | How to use dialysis wisely in cancer patients?. Journal of Onco-Nephrology, 2021, 5, 79-86.   | 0.6 | 1         |
| 4  | Individualizing renal cell carcinoma treatment through biomarkers discovery in the era of immune checkpoint inhibitors: where do we stand?. Current Opinion in Urology, 2021, 31, 236-241.  | 1.8 | 4         |
| 5  | Risk of acute kidney injury in cancer patients after iodinated contrast medium administration and prophylactic strategies: Summary from the most recent guidelines. Journal of Onco-Nephrology, 2021, 5, 114-119.                   | 0.6 | 1         |
| 6  | Management of the kidney transplant patient with Cancer: Report from a Multidisciplinary Consensus Conference. Transplantation Reviews, 2021, 35, 100636.   | 2.9 | 4         |
| 7  | Overweight-obesity is associated with decreased vitamin K2 levels in hemodialysis patients. Clinical Chemistry and Laboratory Medicine, 2021, 59, 581-589.  | 2.3 | 5         |
| 8  | Playing the Devil's Advocate: Should We Give a Second Chance to mTOR Inhibition in Renal Clear Cell Carcinoma? – ie Strategies to Revert Resistance to mTOR Inhibitors. Cancer Management and Research, 2021, Volume 13, 7623-7636. | 1.9 | 6         |
| 9  | The Vessels-Bone Axis: Iliac Artery Calcifications, Vertebral Fractures and Vitamin K from VIKI Study.<br>Nutrients, 2021, 13, 3567.  | 4.1 | 6         |
| 10 | The basics of onco-nephrology in the renal clinic. Journal of Nephrology, 2020, 33, 1143-1149.  | 2.0 | 3         |
| 11 | KDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantation. Kidney International, 2020, 98, 1407-1418.                                   | 5.2 | 8         |
| 12 | P1558THE "HOME JAIL HEMODIALYSIS―PROJECT IN MILAN, ITALY: AN UNIQUE EXPERIENCE ABLE TO SAVE MONEY AND IMPROVE SECURITY. Nephrology Dialysis Transplantation, 2020, 35, .  | 0.7 | 0         |
| 13 | KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, andÂmanaging kidney cancer. Kidney International, 2020, 98, 1108-1119.   | 5.2 | 26        |
| 14 | Vitamin K and Kidney Transplantation. Nutrients, 2020, 12, 2717.  | 4.1 | 6         |
| 15 | Safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma: a systematic review and meta-analysis. Expert Opinion on Drug Safety, 2020, 19, 1329-1338.   | 2.4 | 64        |
| 16 | Exploring the Spectrum of Kidney Ciliopathies. Diagnostics, 2020, 10, 1099.   | 2.6 | 8         |
| 17 | Acute kidney injury from contrast-enhanced CT procedures in patients with cancer: white paper to highlight its clinical relevance and discuss applicable preventive strategies. ESMO Open, 2020, 5, e000618.                        | 4.5 | 9         |
| 18 | Chronic kidney disease as a complication of cancer, with special focus on kidney and urothelial tumors., 2020,, 299-306.e1.   |     | 0         |

| #  | Article  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Oral Calcitriol Use, Vertebral Fractures, and Vitamin K in Hemodialysis Patients: A Cross-Sectional Study. Journal of Bone and Mineral Research, 2020, 36, 2361-2370.  | 2.8 | 2         |
| 20 | Immunotherapy in Dialysis-Dependent Cancer Patients: Our Experience in Patients With Metastatic Renal Cell Carcinoma and a Review of the Literature. Clinical Genitourinary Cancer, 2019, 17, e903-e908.   | 1.9 | 30        |
| 21 | Management of kidney cancer patients: 2018 guidelines of the Italian Medical Oncology Association (AlOM). Tumori, 2019, 105, 3-12.   | 1.1 | 10        |
| 22 | Summary of the International Conference on Onco-Nephrology: an emerging field in medicine. Kidney International, 2019, 96, 555-567.  | 5.2 | 47        |
| 23 | Management of targeted therapies in cancer patients with chronic kidney disease, or on haemodialysis:<br>An Associazione Italiana di Oncologia Medica (AlOM)/Societa' Italiana di Nefrologia (SIN)<br>multidisciplinary consensus position paper. Critical Reviews in Oncology/Hematology, 2019, 140, 39-51. | 4.4 | 11        |
| 24 | The adjuvant treatment of kidney cancer: a multidisciplinary outlook. Nature Reviews Nephrology, 2019, 15, 423-433.  | 9.6 | 68        |
| 25 | Prognostic impact of neutrophil-to-lymphocyte ratio in renal cell carcinoma: a systematic review and meta-analysis. Immunotherapy, 2019, 11, 631-643.  | 2.0 | 38        |
| 26 | Acute Kidney Injury in Oncology and Tumor Lysis Syndrome. , 2019, , 234-250.e1.  |     | 1         |
| 27 | Safety and Efficacy of Pazopanib in First-Line Metastatic Renal-Cell Carcinoma With or Without Renal Failure: CORE-URO-01 Study. Clinical Genitourinary Cancer, 2019, 17, e150-e155.   | 1.9 | 9         |
| 28 | Kidney transplantation in patients with previous renal cancer: a critical appraisal of current evidence and guidelines. Journal of Nephrology, 2019, 32, 57-64.  | 2.0 | 16        |
| 29 | Single nucleotide polymorphisms in angiogenesis-related genes and outcomes from antiangiogenic therapies in renal cell carcinoma: really a step towards personalized oncology, or not at all?. Annals of Translational Medicine, 2019, 7, S15-S15.   | 1.7 | 1         |
| 30 | Prognostic impact of neutrophil-to-lymphocyte ratio in renal cell carcinoma: A systematic review and meta-analysis Journal of Clinical Oncology, 2019, 37, 572-572.  | 1.6 | 0         |
| 31 | Lenvatinib-induced renal failure: two first-time case reports and review of literature. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 379-385.   | 3.3 | 27        |
| 32 | Acute Kidney Injury in Cancer Patients. Contributions To Nephrology, 2018, 193, 137-148.   | 1.1 | 18        |
| 33 | Urothelial cancer: Once there were urologists, now oncologists joined, what about nephrologists?. Journal of Onco-Nephrology, 2018, 2, 3-5.  | 0.6 | 3         |
| 34 | Opening an onconephrology clinic: recommendations and basic requirements. Nephrology Dialysis Transplantation, 2018, 33, 1503-1510.  | 0.7 | 31        |
| 35 | Should CARMENA Really Change our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy. Targeted Oncology, 2018, 13, 705-714.   | 3.6 | 35        |
| 36 | Cigarette Smoking is Associated with Decreased Bone Gla-protein (BGP) Levels in Hemodialysis Patients. Current Vascular Pharmacology, 2018, 16, 603-609.   | 1.7 | 6         |

| #  | Article  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | Renal toxicity of anticancer agents targeting vascular endothelial growth factor (VEGF) and its receptors (VEGFRs). Journal of Nephrology, 2017, 30, 171-180.  | 2.0 | 38        |
| 38 | Editorial Comment from Dr Porta <i>et al</i> . to Patterns of care among patients receiving sequential targeted therapies for advanced renal cell carcinoma: A retrospective chart review in the <scp>USA</scp> . International Journal of Urology, 2017, 24, 279-280. | 1.0 | 0         |
| 39 | Introduction to the Journal of Onco-Nephrology. Journal of Onco-Nephrology, 2017, 1, 1-4.  | 0.6 | 9         |
| 40 | CORE-URO-01 study: comparison of safety and efficacy of pazopanib in first-line metastatic renal cell carcinoma (mRCC) with or without renal failure. Annals of Oncology, 2017, 28, vi17.  | 1.2 | 0         |
| 41 | The impact of kidney function on the efficacy and safety of pazopanib in metastatic renal cell carcinoma (mRCC) patients: CORE-URO-01 study Journal of Clinical Oncology, 2017, 35, e16063-e16063.   | 1.6 | 0         |
| 42 | Harmonization of Renal Function Assessment Is Needed Throughout the Whole Process of Anticancer Drug Development. Journal of Clinical Oncology, 2016, 34, 2429-2430.   | 1.6 | 5         |
| 43 | Transplantation of kidneys with tumors. Journal of Nephrology, 2016, 29, 163-168.  | 2.0 | 9         |
| 44 | Glomerular diseases and cancer: evaluation of underlying malignancy. Journal of Nephrology, 2016, 29, 143-152.   | 2.0 | 45        |
| 45 | Onco-nephrology: a decalogue: TableÂ1 Nephrology Dialysis Transplantation, 2016, 31, 515-519.  | 0.7 | 63        |
| 46 | Retrospective analysis on safety and efficacy of everolimus in treatment of metastatic renal cancer patients receiving dialysis. Future Oncology, 2015, 11, 3159-3166.   | 2.4 | 10        |
| 47 | Renal effects of targeted anticancer therapies. Nature Reviews Nephrology, 2015, 11, 354-370.  | 9.6 | 95        |
| 48 | Renal cancer in kidney transplanted patients. Journal of Nephrology, 2015, 28, 659-668.  | 2.0 | 38        |
| 49 | Renal toxicity of anticancer agents targeting HER2 and EGFR. Journal of Nephrology, 2015, 28, 647-657.   | 2.0 | 33        |
| 50 | Renal Cell Carcinoma: From Molecular Biology to Targeted Therapies. , 2015, , 555-575.   |     | 0         |
| 51 | Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey. BJU International, 2012, 110, 692-698.  | 2.5 | 39        |
| 52 | Inosine monophosphate dehydrogenase variability in renal transplant patients on longâ€ŧerm mycophenolate mofetil therapy. British Journal of Clinical Pharmacology, 2010, 69, 38-50.   | 2.4 | 39        |
| 53 | Severe Symptomatic Hyponatremia During Sibutramine Therapy: A Case Report. American Journal of Kidney Diseases, 2008, 52, 137-139.   | 1.9 | 16        |
| 54 | Intermittent haemodiafiltration in refractory congestive heart failure: BNP and balance of inflammatory cytokines. Nephrology Dialysis Transplantation, 2007, 22, 2013-2019.   | 0.7 | 46        |

| #  | Article  | IF  | CITATIONS |
|----|--|-----|-----------|
| 55 | Nephrological management of renal cell carcinoma (RCC) patients: A narrative review. Journal of Onco-Nephrology, 0, , 239936932210984. | 0.6 | 0         |